3 Recruiting Recurrent B-Cell Non-Hodgkin Lymphoma Phase 2 Clinical Trials
Active phase 2 studies for recurrent b-cell non-hodgkin lymphoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Recurrent B-Cell Non-Hodgkin Lymphoma studiesPhase 2 Studies for Recurrent B-Cell Non-Hodgkin Lymphoma
🟢 Recruiting Phase1 / Phase2
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
📍 Northwestern University — Chicago, Illinois
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔